Lodoxamide tromethamine
Alomide (lodoxamide tromethamine) is a small molecule pharmaceutical. Lodoxamide tromethamine was first approved as Alomide on 1993-09-23. It is used to treat keratoconjunctivitis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Alomide
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lodoxamide tromethamine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALOMIDE | Novartis | N-020191 RX | 1993-09-23 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alomide | New Drug Application | 2023-05-10 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
94 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | 2 | 4 | 7 | 20 | 8 | 40 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 3 | 3 | 1 | — | 7 |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | 3 | 1 | 4 | |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | 1 | 1 | 1 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 2 | 1 | — | 3 |
| Traumatic brain injuries | D000070642 | S06 | — | — | 1 | 1 | — | 2 | |
| Autism spectrum disorder | D000067877 | F84.0 | — | — | — | 1 | — | 1 | |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 1 | — | 1 |
| Cognition | D003071 | EFO_0003925 | — | — | — | 1 | — | 1 | |
| Menopause | D008593 | EFO_0003922 | N95 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | F14 | 2 | 2 | — | — | — | 3 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 2 | — | — | — | 2 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | 2 | — | — | — | 2 |
| Bulimia nervosa | D052018 | EFO_0005204 | F50.2 | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 6 | — | — | — | — | 6 | ||
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | — | — | — | — | 1 |
| Pediatric obesity | D063766 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | F17 | — | — | — | — | 1 | 1 | |
| Bulimia | D002032 | F50.2 | — | — | — | — | 1 | 1 | |
| Feeding behavior | D005247 | — | — | — | — | 1 | 1 | ||
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | 1 | 1 | |
| Sleep | D012890 | GO_0030431 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LODOXAMIDE TROMETHAMINE |
| INN | — |
| Description | Alomide (lodoxamide tromethamine) is a small molecule pharmaceutical. Lodoxamide tromethamine was first approved as Alomide on 1993-09-23. It is used to treat keratoconjunctivitis in the USA. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1.NC(CO)(CO)CO.NC(CO)(CO)CO |
Identifiers
| PDB | — |
| CAS-ID | 63610-09-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989725 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 34 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,226 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more